Is GDTC diluting shareholders?

Read three numbers together: shares outstanding over time (11.8M as of 2025-12-31), warrants that can convert into new shares, and how much cash runway remains. A company short on cash with live registrations is structurally likely to issue shares.

Where do these numbers come from?

SEC EDGAR only: the XBRL company-facts API for shares, warrants and cash, and filing metadata for registrations and pricings. Every figure shows its source form, and nothing here is estimated by us beyond the arithmetic stated next to it.

Why might a warrant tranche be missing from the table?

The tranche table is built from the dimensions the company tagged in its own 10-Q or 10-K XBRL. A tranche the filer chose not to dimension does not appear, and its absence proves nothing: the exhibits remain the ground truth. Everything shown carries the filing it came from.

Dilution profile // every instrument, one screen, from SEC filings

CytoMed Therapeutics Ltd (GDTC)

CIK 1873093 · all EDGAR filings →

Overall dilution risk

HIGHworst of 2 computed signals (offering ability)

= the worst band among the computed sub-ratings, no hidden weighting

not every sub-rating was computable; treat as a floor

Offering ability

HIGHF-3 on file 2025-06-13

= is there a registration (S-1/S-3 family) on file without a later withdrawal

no structured fee data on the live registrations, so this is a yes/no, not a size

Overhead supply

NOT COMPUTEDno warrant count tagged in XBRL

= warrant shares outstanding divided by current shares outstanding

absence of a tag is not proof of absence of warrants

Historical dilution

LOW+3% O/S in 3y

= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative

Cash need

NOT COMPUTEDrunway not computable from latest facts

= cash vs trailing operating burn

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

Latest: 11.8M shares as of Dec 31, 2025 (20-F).

Cash runway

Not enough filing data

can’t compute a runway

Full breakdown: cash runway tool

Warrants

No warrant figures tagged in this filer’s XBRL facts. That means the company has not reported them in structured form; it does not prove no warrants exist. The exhibits are the ground truth.

Convertible notes

The latest 10-Q/10-K instance document could not be checked just now, so nothing is shown rather than guessed. Try again shortly.

Registrations and offerings

F-3Jun 13, 2025no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 1 executed · 0 registered.

EXECUTEDAug 18, 2025Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →

EFFECTIVEJun 23, 2025SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDJun 13, 2025F-3 registration — capacity to sell shares, not a sale yetF-3 →

EXECUTEDApr 17, 2023Final prospectus — offering priced (typical for IPOs and marketed share deals)424B4 →

MARKETINGMar 31, 2023Free-writing prospectus — offering being marketedFWP →

EFFECTIVEMar 31, 2023SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDMar 30, 2023F-1/A registration — capacity to sell shares, not a sale yetF-1/A →

REGISTEREDMar 28, 2023F-1/A registration — capacity to sell shares, not a sale yetF-1/A →

REGISTEREDMar 16, 2023F-1/A registration — capacity to sell shares, not a sale yetF-1/A →

MARKETINGFeb 27, 2023Free-writing prospectus — offering being marketedFWP →

REGISTEREDFeb 21, 2023F-1/A registration — capacity to sell shares, not a sale yetF-1/A →

REGISTEREDFeb 1, 2023F-1/A registration — capacity to sell shares, not a sale yetF-1/A →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full GDTC workspace